SFPQ levels were found to be decreased in the postmortem brains of patients with rapidly progressing AD (rpAD), sporadic Creutzfeldt–Jakob disease (sCJD, a rapidly progressive form of dementia), and in 3xTg (amyloid precursor protein [APP]/PS1/Tau) mice. This evidence concerns the gene APP and Alzheimer disease.